OTC Hearing Aids: What They Cost and Who They Fit

Since October 17, 2022, hearing aids have been sold in the United States without a prescription, a hearing test or an appointment. The Food and Drug Administration created the over-the-counter category for adults aged 18 and over with perceived mild to moderate hearing loss, and the price gap it opened is large. The Government Accountability Office, in report GAO-24-106854 published on May 7, 2024, found that prescription hearing aids ranged from 1,000 to 6,000 dollars per pair while over-the-counter hearing aids ranged from around 200 dollars to over 1,000 dollars.

That is a difference of thousands of dollars for devices that, at the top of the over-the-counter range, use broadly similar hardware. Whether the cheaper route is right for a particular person comes down to three questions: how much hearing has been lost, whether the loss is the same in both ears, and how much of the value in a hearing aid comes from the professional fitting rather than the device.

Who the over-the-counter category is actually for

The FDA is specific, and the boundaries are worth taking literally.

Over-the-counter hearing aids are intended for adults 18 years of age and older with perceived mild to moderate hearing loss. The agency states that anyone younger than 18 needs to buy hearing aids by prescription, and that over-the-counter devices are not for the treatment of severe or profound hearing loss. It also notes that these devices are limited in their maximum output and may not be adequate for more severe losses.

The word doing the most work in that definition is “perceived”. No test is required. You are self-diagnosing, which is reasonable for a device with a low ceiling on output and a return window, and unreasonable if the reason for the hearing change is something a device cannot address.

The conditions that mean a doctor first, not a purchase first

The FDA lists circumstances where a hearing health care professional or physician should be seen rather than a box opened. Among them:

• Your hearing changed suddenly in the past six months.
• Your hearing is worse in one ear than the other.
• Your ear feels painful.
• You saw blood, pus or fluid coming out of your ear.
• Your ear has a birth defect.

A hearing check is not on most standard adult preventive screening timelines before later middle age, which is part of why hearing loss goes unaddressed for years. Sudden change and asymmetry are the two most important items on that list, because both can indicate conditions where a device is the wrong response and where time matters. A hearing aid will amplify sound either way, which is exactly the problem: it can make the symptom tolerable while leaving the cause unexamined.

How many people this applies to

The National Institute on Deafness and Other Communication Disorders reports, drawing on National Health and Nutrition Examination Survey data from 2015 to 2020, that the prevalence of disabling hearing loss rises steeply with age: about 5 percent of adults aged 45 to 54, 10 percent of those 55 to 64, 22 percent of those 65 to 74, and 55 percent of those 75 and older.

The institute also reports, from its own epidemiology section as of May 2016, that about 28.8 million US adults could benefit from using hearing aids. Among adults aged 70 and older who could benefit, fewer than one in three, around 30 percent, has ever used them. Among those aged 20 to 69, the figure is approximately 16 percent.

That gap between people who would benefit and people who have tried is the entire policy rationale for the over-the-counter category. Cost was one barrier. The requirement to book an appointment, take a test and then be sold a device by the person who administered the test was another.

The four things being sold, and what separates them

Four categories of product sit on the shelf and online, and the labels blur in marketing copy.

Price figures for prescription and over-the-counter devices are the ranges reported by the Government Accountability Office in May 2024. The sub-categories within over-the-counter reflect how the market has segmented since the rule took effect rather than a regulatory distinction, and prices move.

The meaningful technical line runs between self-fitting and preset. A self-fitting device runs a hearing check and shapes amplification across frequency bands to the result. A preset device gives you a few modes. Most hearing loss is not flat; it typically affects higher frequencies first, which is why consonants blur before vowels do and why a speaker sounds mumbled rather than quiet. A device that simply raises everything makes the room louder without making speech clearer, which is the single most common reason people abandon cheap amplification.

What the professional fitting is actually worth

The honest case for paying several times more is not that prescription hardware is several times better. It is that three services come with it.

The first is an examination and a measured audiogram, which establishes what the loss actually is and whether anything else is going on. The second is verification, in which the clinician measures what the device is doing inside your ear canal rather than trusting the manufacturer’s curve. The third is follow-up adjustment over months, because adaptation to amplification is gradual and the first setting is rarely the final one.

For someone with a straightforward, symmetrical, mild high-frequency loss, those services are worth something but not thousands. For someone with an unusual loss pattern, a significant difference between ears, tinnitus, or a history of ear surgery or infection, they are the main thing being purchased and the device is incidental.

The five-year cost, which is where the decision changes shape

Comparing a 400 dollar purchase against a 4,000 dollar purchase is misleading, because hearing aids are consumables with a service life measured in years, and because prescription prices typically bundle years of visits.

Here is the arithmetic over five years, assuming over-the-counter devices are replaced once in that period and prescription devices are not, with professional visits priced separately for the over-the-counter route.

Those device prices are illustrative points inside the ranges the Government Accountability Office reported, not quoted statistics. The pattern they show is the useful part: the over-the-counter route saves real money even after a mid-period replacement, and a self-fitting device plus two paid clinical visits still lands well below a bundled prescription purchase. The gap narrows considerably if a device is abandoned in a drawer, which is the most expensive outcome of all at any price.

Insurance will probably not help, and it is worth knowing why

Original Medicare does not cover hearing aids. The programme states plainly that Original Medicare does not cover hearing aids or exams for fitting hearing aids. It does cover diagnostic hearing and balance exams under Part B where a doctor or other health care provider orders them to find out whether medical treatment is needed, which is a narrower thing than a fitting appointment.

Many Medicare Advantage plans do include a hearing aid benefit, often through a specific network and a specific set of models, and the value of that benefit varies enormously between plans. If hearing is a live issue, it belongs on the comparison list alongside the usual items when choosing between Medicare Advantage and Original Medicare, because it is one of the clearest cases where the two paths differ in cash terms.

For people under 65, employer health plans vary and many exclude hearing aids entirely. Health savings account and flexible spending account funds can generally be used for hearing aids, which effectively discounts the purchase by your marginal tax rate. For older households this sits alongside the wider question of which care costs any insurance actually pays for, where hearing is one of several routinely excluded items.

What the research does and does not say about cognition

Hearing aids are frequently marketed with the claim that they protect against dementia. The evidence is more specific and more interesting than the marketing.

The ACHIEVE trial, published in The Lancet and presented at the Alzheimer’s Association International Conference on July 18, 2023, randomised 977 adults aged 70 to 84 to a hearing intervention or a health education control for three years. Across the whole study population, the comparison of hearing intervention versus control was negative: no significant difference in the rate of cognitive change.

In a prespecified subgroup drawn from the Atherosclerosis Risk in Communities study, 238 participants who were at higher risk of cognitive decline, the hearing intervention was associated with a 48 percent reduction in three-year cognitive change compared with control.

The responsible reading of that is narrow. In older adults already at elevated risk of cognitive decline, treating hearing loss appeared to slow it substantially. In a generally healthy older population over three years, it did not show a measurable cognitive effect. A trial of three years is also short relative to the time over which cognitive decline unfolds. Anyone selling a hearing aid as dementia prevention is extending a subgroup finding well past what the trial supports.

The better reason to treat hearing loss is the immediate one. Conversation at a dinner table stops being work. You stop declining invitations to loud restaurants. That is a quality-of-life argument and it does not need a biomarker.

A decision rule

1. If any FDA red flag applies, see a physician or hearing professional before buying anything. Sudden change in the past six months, worse hearing in one ear, pain, discharge: these are reasons to be examined, not reasons to amplify.
2. Get a diagnostic hearing exam if a provider will order one. Part B covers it where ordered to determine whether medical treatment is needed, and knowing your actual audiogram makes every subsequent decision better, including the decision to buy cheaply.
3. If the loss is mild, symmetrical and gradual, start with a self-fitting over-the-counter device. It is the best ratio of capability to cost in the category, and the in-app hearing check is the feature that makes amplification match your loss.
4. Buy only where the return window is at least 30 days and in writing. Adaptation takes weeks. A 14-day window is not long enough to know.
5. Give it four to six weeks of daily wear before judging it. Amplified sound is initially unpleasant and your own voice will sound wrong. That fades. Most abandonment happens in week one.
6. Escalate to a professional if the device does not help enough. The FDA’s own guidance says exactly this. Money spent on an over-the-counter trial is not wasted if it tells you the loss is beyond the category.
7. Go straight to prescription if the loss is severe, asymmetrical, longstanding, or accompanied by tinnitus or a history of ear disease. The ceiling on over-the-counter output means the cheap route will fail, and failing first costs you months.

What this does not solve

Hearing aids are not glasses. Glasses restore an optical signal; hearing aids amplify a signal that a damaged cochlea will still process imperfectly. In a quiet room with one talker the improvement can be dramatic. In a restaurant with hard surfaces and four conversations, even expensive devices struggle, because separating a voice from competing noise is a harder problem than making it louder, and the part of the auditory system that used to do that work is the part that was lost.

Managing expectations is therefore part of making the purchase work. The realistic promise of a well-fitted device is that one-to-one conversation becomes easy again, television becomes comfortable at a normal volume, and group settings become possible with effort rather than impossible. That is a substantial improvement in daily life, and it is not the same as hearing as you did at 25.

The other uncomfortable fact is that the over-the-counter market is young and uneven. The Government Accountability Office noted in May 2024 that it was too soon after implementation of the final rule to assess its effects, and that remains broadly the position: there is not yet a long track record distinguishing good devices from bad ones in this category. Which means the return policy is not a detail. It is the main consumer protection you have.

Where these figures come from

• U.S. Food and Drug Administration, OTC Hearing Aids: What You Should Know
• U.S. Food and Drug Administration, Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids, final rule effective October 17, 2022
• U.S. Government Accountability Office, Over-the-Counter Hearing Aids, GAO-24-106854, May 7, 2024
• National Institute on Deafness and Other Communication Disorders, Quick Statistics About Hearing, drawing on NHANES 2015 to 2020 and NIDCD epidemiology data
• ACHIEVE randomised controlled trial, published in The Lancet, presented July 18, 2023
• Medicare, coverage of hearing and balance exams

General information, current as of October 2026, and not personalised medical advice. Device prices, coverage rules and clinical guidance change; speak with a qualified hearing health care professional about your own hearing and check the primary sources before buying.